LCM
NVCR icon

Lattice Capital Management’s NovoCure NVCR Stock Holding History

Lattice Capital Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-3,100
Closed -$227K – 59
2022
Q4 		$227K Hold
3,100
– – 0.04% 47
2022
Q3 		$236K Hold
3,100
– – 0.38% 47
2022
Q2 		$226K Hold
3,100
– – 0.03% 53
2022
Q1 		$261K Hold
3,100
– – 0.37% 58
2021
Q4 		$233K Buy
+3,100
New +$311K 0.02% 69

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
NA
Nordwand Advisors Radnor, Pennsylvania $572M AUM 23.09% 1-Year Est. Return

Lattice Capital Management's NVCR Position: Q1 2023 in Review

Lattice Capital Management sold out of NovoCure (NVCR) in Q1 2023, closing a stake of 3,100 shares — an estimated $227K sold.

Lattice Capital Management first reported a position in NVCR in Q4 2021 and held it in 5 quarters. The position peaked at $261K in Q1 2022. 295 funds tracked by Wall St. Rank hold NVCR as of Q1 2023.

  • Lattice Capital Management reported no remaining NovoCure position as of Q1 2023 after selling out during the quarter.
  • Lattice Capital Management sold 3,100 NovoCure shares in Q1 2023, an estimated $227K.
  • Lattice Capital Management first reported a position in NovoCure in Q4 2021 and held it in 5 quarters.
  • Lattice Capital Management's NovoCure position peaked at $261K in Q1 2022.
  • 295 funds tracked by Wall St. Rank held NovoCure as of Q1 2023.

Based on Lattice Capital Management's 13F filing for Q1 2023, filed 4 May 2023.